Skip to main content
hello world

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates

PR Newswire - Thu Nov 10, 2022

Company announced first patient dosed in its Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Read more at prnewswire.com